The Belgian spin-off of VIB, ActoGeniX, has garnered a total of €20 million in its first round. GIMV is adding €8 million in a second tranche, with Life Sciences Partners acting as co-lead investor. New investors include Aescap, Ventech and Baekeland Fonds. ActoGeniX is developing a pipeline of therapeutic products based on its TopActTM technology platform, a proprietary delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals. VIB and Ghent University, the original inventors of this technology, transferred the IP to ActoGeniX.
- see the release on the venture round